• Pfizer Loses 6% On Disappointing Ibrance Breast Cancer Outcome

    Pfizer Loses 6% On Disappointing Ibrance Breast Cancer OutcomeShares in Pfizer Inc. (PFE) dropped 6% in after-market trading on Friday after the company reported a disappointing outcome for its Phase 3 PALLAS early breast cancer study.Following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee determined that the trial of Ibrance (palbociclib) plus standard adjuvant endocrine therapy is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS).Patients receiving palbociclib in the study will be advised about next steps by their physicians and long-term follow up will proceed as planned, the company said, adding that no unexpected new safety signals were observed in patients receiving palbociclib.The PALLAS trial compared palbociclib plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy alone in women and men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early (stage 2 and 3) breast cancer.“We are disappointed in this outcome. Breast cancer is a leading cause of death around the world and delaying or preventing the development of metastatic disease is a significant unmet need. PALLAS is a large study with many subgroups and we are actively collaborating to determine if there are patients who may benefit from adjuvant treatment with the palbociclib combination,” said Chris Boshoff of Pfizer Global Product Development.Meanwhile Pfizer CEO Albert Bourla moved to reassure investors, writing that the company’s growth projections are not reliant upon any individual pipeline opportunity. “We remain highly confident in our ability to deliver… a compound annual growth rate for revenues of at least 6% through 2025” he stated.The full results from the PALLAS study will be shared at a later date. Palbociclib is also being studied in patients with high-risk early breast cancer and results from the collaborative PENELOPE-B trial are expected later this year. In the US, Ibrance is already approved for adult patients with HR+, HER2- advanced or metastatic breast cancer.Shares in Pfizer are trading down 3% on a year-to-date basis, and analysts are evenly divided between hold and buy. This gives the stock a Moderate Buy Street consensus with an average price target of $42 (11% upside potential). (See Pfizer stock analysis on TipRanks).Related News: BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A Efgartigimod’s Positive Data Is Good News for Momenta’s Nipocalimab Novavax Seeks To Make 1 Billion Covid-19 Vaccine Doses More recent articles from Smarter Analyst: * Microsoft Informs Journalists Their Services Are No Longer Needed * Yext Earnings Preview: RBC Capital Bullish Into Print * U.S. Retail Giants From Apple To Amazon Curtail Business Due To Nationwide Riots * BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A

    from Yahoo Finance https://ift.tt/2BdEHHs

  • Forget cheap stocks. Why investors should watch ASX gold shares instead

    stacks of gold coins growing higher

    Investors have always sought the protection of gold in cases of recessions and financial crises. Gold was already off to a strong start in 2020 following geopolitical escalations between the US and China, and the US and Iran. The coronavirus pandemic further propped up gold prices to almost record all-time highs.

    This is why investors should be watching ASX gold shares instead of trying to pick ‘cheap’ stocks and dividend traps. 

    Tailwinds for gold 

    Safe-haven buying has been fuelled by the collapse of global equity markets in first quarter of the year. Central banks around the world have their printing machines running overtime in an attempt to cushion the economic repercussions of the coronavirus. Furthermore, interest rates were slashed by major global central banks, with the Reserve Bank of Australia cutting rates to 0.25% and the US Federal Reserve cutting interest rates to zero percent. Printing more money and raising debt should see fiat currencies get devalued. 

    Additionally, China’s decision to curb Hong Kong’s autonomy by pushing forward a controversial national security law and the likelihood of a strong US retaliation will continue to support stronger gold prices, in my opinion. As reported by the BBC, President Donald Trump has said that “this is a tragedy for Hong Kong … China has smothered Hong Kong’s freedom”. Rising tensions could put the US–China trade deal agreed in January at risk. 

    As economies around the world begin to restart economies by relaxing lockdown measures and allowing businesses to reopen, there is the risk of a ‘second wave’ of coronavirus infections. While global equities have rebounded and remain optimistic, a second wave could initiate another broad market sell-off. 

    ASX gold shares

    ASX gold miners are an excellent avenue to gain gold exposure without having to directly invest in the commodity. There are a broad range of gold miners that have differing growth and cost characteristics. 

    Northern Star Resources Ltd (ASX: NST) and Saracen Mineral Holdings Limited (ASX: SAR), for example, have typically been more growth orientated, favouring acquisitions and the expansion of their mining capabilities. Both miners are involved in the joint venture of the KCGM, the largest open pit mine in Australia and the 2nd highest producer of gold. These significant acquisitions have generated immediate revenue and continue to provide the businesses with additional exploration and reserve upside. While I would say Northern Star and Saracen are more volatile and risky investments, their ‘growth’ orientated business models have seen significant capital gains for their long-term investors. 

    Alternatively, Evolution Mining Ltd (ASX: EVN) and Newcrest Mining Limited (ASX: NCM) are more cost-focused with some of the lowest all-in sustaining costs. Evolution and Newcrest are well positioned to leverage off higher gold prices given their low production costs. 

    ASX gold shares are perfect for today’s uncertain and potentially dangerous climate. For investors looking for growth shares, check out our free report below.

    5 “Bounce Back” Stocks To Tame The Bear Market (FREE REPORT)

    Master investor Scott Phillips has sifted through the wreckage and identified the 5 stocks he thinks could bounce back the hardest once the coronavirus is contained.

    Given how far some of them have fallen, the upside potential could be enormous.

    The report is called 5 Stocks For Building Wealth after 50, and you can grab a copy for FREE for a limited time only.

    But you will have to hurry — history has shown the market could bounce significantly higher before the virus is contained, meaning the cheap prices on offer today might not last for long.

    See the 5 stocks

    More reading

    Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Forget cheap stocks. Why investors should watch ASX gold shares instead appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2TWMOPj

  • These ASX shares are set to get a big boost from the next big government stimulus

    ASX Shares skyrocketing

    Speculation that the federal government is readying a large home buyer’s grant could put the building materials sector on an earnings upgrade cycle.

    There are reports that the Morrison government will announce later this week that new home buyers will get a cash handout of between $20,000 to $40,000.

    This fourth round of stimulus is aimed at protecting the home construction industry from falling off a cliff, according to a report on Yahoo.

    New housing grant

    Around 380,000 tradies are expected to benefit from the generous cash handout for existing and first-home buyers looking to purchase newly constructed dwellings.

    There’s even talk that the grant will be made available for home renovations, although we shouldn’t get too excited just yet as nothing is confirmed.

    The only thing that seems to be reasonably certain is that the new housing grant will at least match the $21,000 offered by the Rudd government during the global financial crisis.

    Building to an upgrade

    If the new measure works as intended and provides a strong pipeline of home construction activity, brokers will likely scramble to upgrade their earnings expectations for a number of ASX shares.

    These include building materials companies Boral Limited (ASX: BLD), CSR Limited (ASX: CSR), Adbri Ltd (ASX: ABC) and James Hardie Industries plc (ASX: JHX).

    It’s probably no coincidence that two of the four shares are among the top five best performers on the S&P/ASX 200 Index (Index:^AXJO) today. The pair is Boral and Adbri as they are the worst in the group and would probably have the most to gain.

    More stimulus in the pipeline

    But the industry may also get a second tailwind. State governments are also tipped to announce separate stimulus on top of the up to $40k grant.

    Governments are forced to act after the industry’s peak body, Master Builders Australia, predicted 400,000 building businesses and 1.2 million jobs were in jeopardy due to housing downturn.

    The association is pushing for renovations to be included in the package as it claims that will generate $7 billion in economic activity and 24,036 jobs.

    “Work for builders and tradies in 2020/21 is fast evaporating and the indications are that 2021/22 will not be much better,” said the chief executive of Master Builders, Denita Wawn.

    Other ASX stocks to benefit

    If renovations are included, it won’t only be building materials companies that will be smiling. Hardware retailers owned by Wesfarmers Ltd (ASX: WES) and Metcash Limited (ASX: MTS) are also likely to benefit.

    If you are wondering why the share prices of property developers like Stockland Corporation Ltd (ASX: SGP) seem to be in the doldrums today, it’s probably because new housing estate developments only make up a part of their portfolio.

    Unfortunately for them, the other parts (such as shopping malls) are still under significant pressure.

    NEW: Expert names top dividend stock for 2020 (free report)

    When our resident dividend expert Edward Vesely has a stock tip, it can pay to listen. After all, he’s the investing genius that runs Motley Fool Dividend Investor, the newsletter service that has picked huge winners like Dicker Data (+92%), SDI Limited (+53%) and National Storage (+35%).*

    Edward has just named what he believes is the number one ASX dividend stock to buy for 2020.

    This fully franked “under the radar” company is currently trading more than 24% below its all-time high and paying a 6.7% grossed-up dividend.

    The name of this dividend dynamo and the full investment case is revealed in this brand new free report.

    But you will have to hurry — history has shown it can pay dividends to get in early to some of Edward’s stock picks, and this dividend stock is already on the move.

    See the top dividend stock for 2020

    More reading

    Motley Fool contributor Brendon Lau owns shares of James Hardie Industries plc. The Motley Fool Australia owns shares of Wesfarmers Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post These ASX shares are set to get a big boost from the next big government stimulus appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2AwMyPZ